# Dana-Farber/Harvard Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/dana-farber-harvard-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 73.8 |
| Citations | 1,664,646 |
| City | Boston |
| Country | US |
| Description | Dana-Farber/Harvard Cancer Center is a research organisation in Boston, US. OpenAlex records 15,153 works and 1,664,646 citations for it. 1,678 researchers list it as their most recent affiliation. |
| Homepage | https://www.dfhcc.harvard.edu |
| OpenAlex ID | https://openalex.org/I4210134579 |
| Researchers | 1,678 |
| ROR ID | https://ror.org/03pvyf116 |
| Type | healthcare |
| Works | 15,153 |

## University papers

- [Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort](https://scholariq.org/papers/survival-and-prognosis-with-osteosarcoma-outcomes-in-more-than-2000-patients-in/)
- [Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)
- [Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial](https://scholariq.org/papers/comparison-of-mapie-versus-map-in-patients-with-a-poor-response-to-preoperative/)
- [Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation](https://scholariq.org/papers/clinical-acquired-resistance-to-krasg12c-inhibition-through-a-novel-kras-switch/)
- [Recognizing the reagent microbiome](https://scholariq.org/papers/recognizing-the-reagent-microbiome/)
- [Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study](https://scholariq.org/papers/dose-intensified-compared-with-standard-chemotherapy-for-nonmetastatic-ewing/)
- [PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer](https://scholariq.org/papers/pten-loss-mediates-clinical-cross-resistance-to-cdk4-6-and-pi3k-inhibitors-in/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)
- [The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer](https://scholariq.org/papers/the-clinical-landscape-of-cell-free-dna-alterations-in-1671-patients-with/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Corporate Finance and Governance](https://scholariq.org/topics/corporate-finance-and-governance/)
- [Ecology and Vegetation Dynamics Studies](https://scholariq.org/topics/ecology-and-vegetation-dynamics-studies/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Plant Water Relations and Carbon Dynamics](https://scholariq.org/topics/plant-water-relations-and-carbon-dynamics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.